Innate Pharma SA (IPHA)

Market price: $1.52

6 methods not shown

• EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
• EV / Revenue: net debt unavailable — cannot bridge enterprise value to equity
• EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
• P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
• P / B: book value per share is non-positive (negative common equity) — P/B is not meaningful
• DCF (FCFF): base unlevered FCF is non-positive (-52,582,206.11) — nothing to discount; a standard FCFF DCF does not apply

Pre-profit company — earnings-based methods not meaningful.

We can't value this company — not enough of the financial data our methods require is available from its SEC filings.